Vaxart, Inc. (OTC: VXRT) is a Healthcare company (Biotechnology) with a market capitalization of $87M. The Maz Rating grades it against the other companies in its sector.
Vaxart, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.35, Vaxart, Inc. trades at 3.0x trailing earnings, 0.5x sales and 1.3x book value, with an EV/EBITDA of 1.6. Over the last twelve months it generated about $182M of revenue and $29M of net income. It runs a gross margin of 99.3%, an operating margin of 16.6% and a net margin of 16.0%. It shows return on equity of 35.1%, return on invested capital of 55.4% and a free cash flow yield of 36.9%. On the balance sheet: a debt-to-equity ratio of 0.11 and a current ratio of 1.30. Over the past 52 weeks the share price ranged from $0.33 to $0.84, with a beta of 1.06.
Vaxart, Inc. does not currently pay a dividend.
3 Wall Street analyst ratings cover the stock: 3 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Vaxart, Inc. (VXRT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 2.26% / 30% · (Cash+Inv) / Mkt Cap (36m) 59.9% / 30% · Interest income / Revenue 5.08% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 2.26% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 59.9% / 33% · Receivables / Mkt Cap (36m) 28.1% / 49% · Interest income / Revenue 5.08% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 2.26% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 59.9% / 33.33% · Receivables / Mkt Cap (24m) 28.1% / 33.33% · Interest income / Revenue 5.08% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.36% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 37.4% / 33.33% · Receivables / Avg Assets (4Q) 27.5% / 33.33% · Interest income / Revenue 5.08% / 5% | Fail |
| FTSE | Debt / Total Assets 1.66% / 33.33% · (Cash+ST Inv) / Total Assets 44.2% / 33.33% · (Cash+Recv) / Total Assets 64.9% / 33.33% · Interest income / Revenue 5.08% / 5% | Fail |
No. As of September 2026, Vaxart, Inc. (VXRT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Vaxart, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 5.08% of each dividend: Vaxart, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.